MAP Pharmaceuticals has several proprietary product candidates in clinical development which address large market opportunities, including our two most advanced product candidates, Unit Dose Budesonide, or (UDB), for pediatric asthma and MAP0004 for migraine. We announced positive results from Phase 2 clinical studies of UDB and MAP0004 in 2007. We initiated Phase 3 clinical programs for UDB and MAP0004 in 2008.
In addition to our pediatric asthma and migraine programs, our development portfolio includes drug candidates for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and diabetes, as well as therapeutics for other disorders that could benefit from pulmonary delivery.
